AVIA Biosystems, located near Boston, MA, is dedicated to developing and commercializing new products for the biochemical and biophysical characterization of biologics and other biomolecules.
The Company was founded by a highly experienced team with extensive experience in biophysics and the development and commercialization of scientific instruments for biophysical and biochemical characterization.
AVIA’s new product opportunities emerge from direct interaction with scientists in the biopharmaceutical industry and from collaborations with academic or other research institute groups working in the field of biologics. AVIA's products provide effective solutions to common bottlenecks that limit the development and formulation of biologics.
The first product to be developed by AVIA is the fluorescence-based Model 2304 Fully Automated Protein Denaturation System.
The Model 2304 is designed to automate protein stability studies. The primary applications for this new instrument are:
1. The stability testing of protein constructs during discovery and development
2. Biologics formulation stability testing during pre-clinical and clinical development
The AVIA Model 2304 will automatically prepare protein samples for analysis, prepare the requested array of buffer and excipient conditions from bulk solvents, collect the fluorescence data, and process the data for relative stability results for up to 96 protein samples or formulations.
AVIA Biosystems was recently awarded a $1.25M Small Business Innovation Research (SBIR) grant to support the development of this technology and instrument.
For more information contact:
Visit us at PEGS 2014
Boston Seaport World Trade Center May 5-9
Conference booth #133
Attend the Luncheon seminar on Tuesday May 6th 12:45
"Protein Stability and Optimize the Formulation of Biologics”
Ernesto Freire, PhD, Professor of Biology and Biophysics, Johns Hopkins University